Speed Is Not the Accelerator. Accountability Is.

Sarah Sink
3 days ago
3 min read

Speed gets a lot of attention in drug development.

Faster timelines.

Faster tech transfer.

Faster manufacturing readiness.

Faster path to patients.

But speed is rarely what separates strong programs from struggling ones.

Accountability does.

When ownership is clear, programs move forward with confidence. When it is unclear, even talented teams lose momentum.

In complex development programs, accountability is not about assigning blame. It is about creating clarity so decisions can happen without hesitation.

Why Accountability Gets Blurred

Most programs involve multiple organizations and multiple disciplines.

Development teams focus on data.Manufacturing focuses on scalability.

Quality focuses on compliance.

Fill-finish teams focus on aseptic execution and supply continuity.

Sponsors focus on milestones and funding timelines.

Each group is doing its job. The problem appears when responsibilities overlap but ownership does not.

Questions start to emerge:

Who owns readiness for tech transfer?

Who decides when methods are ready?

Who owns risk during sterile fill finish preparation?

When those answers are unclear, decisions slow down.

Accountability and the Cost of Waiting

Programs rarely stop because someone made the wrong decision. They slow down because no one feels empowered to make the right one.

Teams wait for alignment.

They wait for approval.

They wait for someone else to lead the conversation.

Meanwhile, timelines move forward.

This waiting creates hidden delays that do not show up in project plans but become very visible during execution.

Accountability removes hesitation. It gives teams permission to act with confidence.

Why Sterile Fill Finish Demands Clear Ownership

Sterile fill finish is often where accountability gaps become impossible to ignore.

At this stage, timelines are tight and options are limited. Decisions around container closure systems, filtration, scheduling, and aseptic processes must be made decisively.

If ownership is unclear:

Risks get escalated late
Changes ripple backward into manufacturing
Supply planning becomes unstable
Teams operate defensively instead of collaboratively

Programs that define accountability early, including who owns fill-finish readiness, avoid last-minute friction.

Fill finish does not create accountability problems. It exposes them.

The Role of CDMO Partnerships

Accountability becomes even more important when multiple organizations are involved.

Strong CDMO partnerships succeed because ownership is discussed openly:

Who owns decisions
Who owns risk communication
Who owns readiness at each stage

From a business development perspective, this is a major differentiator.

The strongest partnerships are not those with the most meetings. They are the ones where responsibilities are clear enough that decisions move quickly.

Partnership maturity shows up in how accountability is shared, not avoided.

Business Development as a Connector

Business development professionals are often underestimated when it comes to accountability.

BD sees the full picture. They understand sponsor priorities, internal capabilities, and execution realities. That perspective allows them to clarify expectations before work begins.

Strong BD professionals:

Set realistic commitments
Encourage early SME involvement
Align ownership discussions before pressure builds
Help prevent surprises during manufacturing and fill finish

Accountability starts long before execution. It starts during early conversations.

What Strong Programs Do Differently

Programs that maintain momentum tend to share a few behaviors:

Ownership is defined early and revisited often
SMEs know when and how decisions are made
Development, manufacturing, and fill finish stay aligned
Escalation paths are clear
Teams focus on solutions, not responsibility debates

These programs move faster because people know when to act.

Final Thoughts

Drug development is complex. That will never change.

What can change is how clearly ownership is defined.

When accountability exists, teams make decisions faster, partnerships feel stronger, and execution becomes more predictable from development through sterile fill finish.

If your team is evaluating CDMOs or comparing proposals, it is worth asking not only what capabilities exist, but how accountability is structured across the lifecycle.

My guide, How to Compare CDMO Quotes: 10 Factors Beyond Cost helps biotech teams evaluate partners through a broader lens, including communication, ownership, and execution readiness.

Because in drug development, accountability is often the real accelerator.

For more insights and personalized support in navigating the biotech-CDMO landscape, visit www.yourpharmagirl.com and follow Your Pharma Girl on LinkedIn. Whether you need strategic guidance, tailored business development solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.